Paid Clinical Trials Grand Forks
Discover 42 paid clinical trials in Grand Forks, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced CancerAt-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer
Sponsor:
Mayo Clinic
Location:
Code:
NCT05969860
Conditions
Advanced Anal Carcinoma
Advanced Biliary Tract Carcinoma
Advanced Bladder Carcinoma
Advanced Breast Carcinoma
Advanced Carcinoid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Encounter
Home Health Encounter
Quality-of-Life Assessment
Questionnaire Administration
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsFive or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Sponsor:
NRG Oncology
Location:
Code:
NCT05080673
Conditions
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Eligibility Criteria
Sex: All
Age: 50 - 70
Healthy Volunteers: Not accepted
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 MutationEvaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
Sponsor:
Sermonix Pharmaceuticals Inc.
Location:
Code:
NCT05696626
Conditions
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Lasofoxifene in combination with abemaciclib
Fulvestrant in combination with abemaciclib
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerLeveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Sponsor:
Mayo Clinic
Location:
Code:
NCT05051722
Conditions
Endometrial Cancer
Cervical Cancer
Atypical Endometrial Hyperplasia
Cervical Dysplasia
Adnexal Mass
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tampon Collection
Blood Collection
MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims StudyMILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06077760
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
V940
Pembrolizumab
Placebo
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT02201992
Conditions
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Observation
Crizotinib
Laboratory Biomarker Analysis
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder CancerComparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04559139
Conditions
Stage II Gallbladder Cancer AJCC v8
Stage IIA Gallbladder Cancer AJCC v8
Stage IIB Gallbladder Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cisplatin
Gemcitabine Hydrochloride
Lymphadenectomy
Partial Hepatectomy